NCT00975065已完成4 期
A 24-week, Open-label, Randomized, Multi-center, Parallel-group Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Prior Metformin Monotherapy in Comparison to up Titrating Metformin Dose.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Handok Inc.
- 入组人数
- 266
- 试验地点
- 1
- 主要终点
- Hemoglobin A1c at 24 weeks
研究概览
简要总结
The study design of this trial is open-label, randomized, multi-center, parallel-group study.
详细描述
- The progressive nature of T2DM will require the use of combination therapy in many patients over time to achieve and maintain glycemic control. Early combination, compared with maximal dose of monotherapy, could be more effective in lowering glycemia with better tolerability.
- Vildagliptin is a new oral antidiabetic drug acting as a potent and selective inhibitor of dipeptidyl peptidase-4(DPP-4), the enzyme responsible for the rapid degradation of circulating glucagon-like peptide-1. Vildagliptin improves islet function by a mechanism of increasing plasma levels of the active forms of the incretin hormones, GLP-1 and GIP.
- Metformin improves hyperglycemia primarily through its suppression of hepatic gluconeogenesis as well as enhancement of peripheral glucose update. Metformin is the most commonly prescribed first-line antidiabetic drug worldwide, but due to the progressive worsening of blood glucose control during the natural history of type 2 diabetes, combination therapy usually becomes necessary.
- Thus their combination therapy with complimentary action mechanism could be as effective as up titration of monotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Type 2 Diabetes Mellitus who were inadequately controlled (baseline A1c of 7.0~11.0%)on metformin monotherapy (1500mg metformin)for ≥ 2 months before baseline visit
- •Age of 18-80 years
- •Body Mass Index of 18-40 kg/m2
排除标准
- •Type 1 of diabetes
- •Myocardial Infarction, Unstable Angina, or Coronary Artery Bypass Graft within the previous 6 months
- •Congestive Heart Failure (III or NYHA class IV)
- •Liver disease such as cirrhosis or Chronic Active Hepatitis
- •History of Lacticacidemia
- •Use of any Oral Anti-diabetic Drug other than Metformin within the 2 months
- •Use of insulin before screening visit
- •ALT or AST >3 times the upper limit of Normal range
- •Creatinine >1.5 mg/dl
- •Other situation (pregnant or lactating females, history of drug or alcohol abuse, night-shift workers, clinically significant laboratory abnormality on screening or any medical condition that would affect the completion or outcome of the study)
研究组 & 干预措施
Galvus group
Experimental
the combination of metformin plus Vildagliptin:
- vildagliptin 50 mg bid plus metformin 1500mg
- Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy.
干预措施: vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex) (Drug)
Diabex group
Active Comparator
metformin alone arm:
- metformin 1500mg plus metformin 500mg or 1000mg
- Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy
干预措施: metformin 1500mg plus metformin 500mg or 1000mg (Diabex) (Drug)
结局指标
主要结局
Hemoglobin A1c at 24 weeks
时间窗: 32weeks
次要结局
- Hemoglobin A1c at 12 weeks(32weeks)
- Fasting plasma glucose(Self Monitored Blood Glucose) at 24 week(32weeks)
- 2hours post-prandial plasma glucose(Self Monitored Blood Glucose) at 24 week(32weeks)
- Fasting Lipid profiles at 24 week(32weeks)
- Body weight at 24 week(32weeks)
- Hypoglycemic events, Gastro-Intestinal events, other adverse events at each visit(32weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination TherapyType 2 Diabetes MellitusNCT01444248Handok Inc.168
招募中
2 期
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal CancerColorectal CancerNCT06293014Henan Cancer Hospital224
已完成
3 期
Study of a New Medical Device in Gel Formulation Versus Calgel® for the Topical Treatment of Teething in InfantsPain TeethNCT02931357Ricerfarma S.r.l54
已完成
3 期
A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and SafetyDiabetesNCT02491528Tonghua Dongbao Pharmaceutical Co.,Ltd563
已完成
4 期
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)NCT01659775LG Life Sciences389